Home » Zealand Pharma Presents New Preclinical Data on ZP2929 in Disease Models for Diabetes and Obesity
Zealand Pharma Presents New Preclinical Data on ZP2929 in Disease Models for Diabetes and Obesity
Zealand Pharma, a biopharmaceutical company based in Denmark, has presented new data from preclinical studies with ZP2929, a novel glucagon/GLP-1 dual agonist drug candidate in preclinical development for the treatment of Type 2 diabetes and obesity.
PharmaLive
PharmaLive
Upcoming Events
-
07May
-
14May
-
30May